Advanced Medical Solutions Group Regulatory News (AMS)

15 July 2025

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Half Year Trading Update

~ Strong performance, integrations progressing well ~

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, today announces a trading update for the six months ended 30 June 2025.

Strong underlying momentum in our core surgical product portfolio has continued to drive robust growth during the first half of the year. The integration of Peters Surgical and Syntacoll is progressing well with initial commercial synergies already contributing positively to surgical sales growth. As anticipated, the restructuring of Woundcare was successfully completed by the end of March, resulting in improved margins for that business from the second quarter.

The Group expects to report Half Year 2025 revenues of approximately £110 million (H1 2024: £68.0 million), and adjusted EBITDA of £24.0 - £24.5 million (H1 2024: £18.2 million). This performance remains in line with expectations and, underpinned by continued momentum in the business, the Board continues to be confident in meeting full-year consensus forecasts.

The Group expects to announce its interim results on 17 September 2025. 

Chris Meredith, Chief Executive Officer of AMS, said: "One year on from successfully completing the acquisition of Peters Surgical, it is a good moment to take stock of the excellent integration progress to date, both operationally and in terms of strategic alignment. On the commercial front, we have been pleased to see early synergies already beginning to translate into top-line growth. We remain fully focused on delivering longer-term, significant synergies as integration continues. In parallel, our newly restructured Woundcare business has entered a new phase and is now making a steady contribution to the Group. Underpinned by our core surgical product portfolio, we are pressing ahead to deliver strong growth at the Group level."

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

ICR Healthcare Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone AMS@icrhealthcare.com

Investec Bank PLC (NOMAD & Joint Broker) Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

Berenberg (Joint Broker) Tel: +44 (0)20 3207 7800

Toby Flaux / Detlir Elezi / Yasmina Benchekroun

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.